Table 2.
Fatty acid profile of plasma free fatty acids (mg/dL) in persons with no cognitive impairment (NCI), mild cognitive impairment (MCI) or Alzheimer’s disease (AD)1
| NCI (n = 10) | MCI (n = 7) | AD (n = 9) | |
|---|---|---|---|
| Palmitate (16 : 0) | 4.7 ± 2.5* | 3.0 ± 1.2 | 3.0 ± 1.0 |
| Stearate (18 : 0) | 4.0 ± 1.0 | 3.1 ± 1.6 | 3.4 ± 1.0 |
| Σ Saturates | 9.0 ± 3.5 | 6.3 ± 2.8 | 6.7 ± 2.0 |
| Oleate (18 : 1n-9) | 4.5 ± 3.5a | 1.0 ± 0.4b | 0.8 ± 0.9c |
| Oleate isomers | 1.2 ± 1.5a | 0.5 ± 0.5ab | 0.2 ± 0.2b |
| 22 : 1n-9 | 1.5 ± 0.8 | 0.9 ± 1.0 | 0.1 ± 0.004 |
| Σ Monounsaturates | 7.1 ± 5.0a | 2.4 ± 1.1b | 1.2 ± 1.2c |
| Linoleate | 1.7 ± 1.3a | 0.4 ± 0.1b | 0.3 ± 0.4b |
| Σ n-6 polyunsaturates | 2.4 ± 1.4a | 1.1 ± 0.2b | 1.0 ± 0.4b |
| α-linolenate | 0.2 ± 0.1 | 0.3 ± 0.2 | 0.1 ± 0.03 |
| Docosahexaenoate | 0.1 ± 0.04 | 0.03 ± 0.02 | 0.1 ± 0.05 |
| Σn-3 polyunsaturates | 0.5 ± 0.3 | 1.1 ± 1.0 | 0.3 ± 0.1 |
| SUM | 18.9 ± 9.6a | 10.8 ± 4.2b | 9.1 ± 3.2b |
*
Mean ± SD;
1
arachidonate, eicosapentaenoate and n-3 docosapen-taenoate are not shown because they were present at <0.1 mg/dL;
a,b,c
Different superscripts denote a statistically significant between groups (p ≤ 0.05; Kruskal-Wallis, followed by Mann-Whitney test).